174:@0.086567:0.957873:0.109686:0.957873:0.109686:0.938882:0.086567:0.938882:0.007222:0.007307:0.008591
7:@0.038824:0.559752:0.060302:0.559752:0.060302:0.512274:0.038824:0.512274:0.021478
CHAPTER 7:@0.117647:0.067123:0.189199:0.067123:0.189199:0.047044:0.117647:0.047044:0.009172:0.009650:0.008799:0.008861:0.007388:0.007906:0.009359:0.003320:0.007097
Cancer is a genomic disease and tumors acquire somatic mutations throughout their :@0.117647:0.121273:0.856961:0.121273:0.856961:0.100900:0.117647:0.100900:0.014974:0.009085:0.011596:0.008994:0.009039:0.007807:0.006551:0.005615:0.007670:0.006551:0.009291:0.006551:0.009656:0.009039:0.011596:0.010843:0.017645:0.005547:0.008994:0.006551:0.011391:0.005615:0.007873:0.009291:0.009291:0.007875:0.009039:0.006551:0.009085:0.011596:0.011391:0.006551:0.006166:0.011413:0.017485:0.010843:0.007624:0.007670:0.006551:0.009291:0.008994:0.010706:0.011413:0.005615:0.007442:0.009039:0.006551:0.007875:0.010843:0.017577:0.008811:0.006437:0.005547:0.008994:0.006551:0.017280:0.011071:0.006551:0.008811:0.006437:0.005547:0.010843:0.011619:0.007670:0.006551:0.006620:0.011459:0.007442:0.010820:0.011413:0.009930:0.011299:0.010820:0.011071:0.006437:0.006551:0.006620:0.011299:0.009039:0.005615:0.007807:0.004109
origin and evolution. Some of these mutations give a tumor growth advantage over nor-:@0.117647:0.141852:0.852941:0.141852:0.852941:0.121479:0.117647:0.121479:0.010843:0.007807:0.005615:0.009861:0.005615:0.011756:0.004154:0.009085:0.011596:0.011391:0.004154:0.009336:0.009633:0.010934:0.004908:0.011071:0.006437:0.005547:0.010843:0.011756:0.004497:0.004154:0.010592:0.010843:0.017488:0.009039:0.004154:0.010843:0.006209:0.004154:0.006620:0.011299:0.009039:0.007875:0.009039:0.004154:0.017280:0.011071:0.006551:0.008811:0.006437:0.005547:0.010843:0.011619:0.007670:0.004154:0.009861:0.005547:0.009633:0.009039:0.004154:0.009291:0.004154:0.006163:0.011413:0.017485:0.010843:0.007807:0.004154:0.009861:0.007442:0.010866:0.014723:0.006620:0.011459:0.004154:0.009291:0.011322:0.009838:0.009085:0.011391:0.006551:0.009199:0.009656:0.009039:0.004154:0.010866:0.009633:0.009039:0.007807:0.004154:0.011596:0.010843:0.007300:0.007533
mal cells (driver mutations) and most do not have selective effect (passenger mutations). :@0.117647:0.162431:0.857096:0.162431:0.857096:0.142058:0.117647:0.142058:0.017577:0.009405:0.005250:0.003972:0.008994:0.008948:0.005387:0.005250:0.007670:0.003972:0.006939:0.011391:0.007807:0.005547:0.009633:0.009039:0.007807:0.003972:0.017280:0.011073:0.006549:0.008811:0.006437:0.005547:0.010843:0.011619:0.007670:0.006939:0.003972:0.009085:0.011596:0.011391:0.003972:0.017485:0.010957:0.007510:0.006437:0.003972:0.011322:0.011048:0.003972:0.011596:0.010820:0.006437:0.003972:0.011391:0.008925:0.009633:0.009039:0.003972:0.007875:0.008948:0.005182:0.009106:0.009108:0.006437:0.005547:0.009635:0.009039:0.003972:0.009039:0.005969:0.005787:0.009108:0.009108:0.006437:0.003972:0.006939:0.011365:0.009291:0.007533:0.007875:0.009039:0.011459:0.009656:0.009039:0.007807:0.003972:0.017280:0.011071:0.006551:0.008811:0.006437:0.005547:0.010843:0.011619:0.007670:0.006939:0.004497:0.004109
Regardless, somatic mutations, including structural variants (SVs), uniquely identify and :@0.117647:0.183009:0.857027:0.183009:0.857027:0.162636:0.117647:0.162636:0.013696:0.009039:0.009861:0.009085:0.007442:0.011528:0.005182:0.009039:0.007533:0.007670:0.004497:0.003401:0.007875:0.010843:0.017577:0.008811:0.006437:0.005547:0.008994:0.003401:0.017280:0.011071:0.006551:0.008811:0.006437:0.005547:0.010843:0.011619:0.007670:0.004497:0.003401:0.005615:0.011596:0.008765:0.004908:0.011345:0.011391:0.005615:0.011459:0.009861:0.003401:0.007510:0.006437:0.007967:0.011345:0.009108:0.006163:0.011413:0.007898:0.009405:0.005250:0.003401:0.009838:0.009085:0.007807:0.005798:0.009085:0.011391:0.006437:0.007670:0.003401:0.006939:0.010112:0.015089:0.007670:0.006939:0.004497:0.003401:0.011413:0.011756:0.005547:0.010706:0.011345:0.008948:0.005182:0.009724:0.003401:0.005545:0.011322:0.009039:0.011391:0.006437:0.005615:0.006506:0.009724:0.003401:0.009085:0.011596:0.011391:0.004109
characterize a tumor and can be exploited in different ways. Mainly through targeted :@0.117647:0.203588:0.857137:0.203588:0.857137:0.183215:0.117647:0.183215:0.008765:0.011391:0.009085:0.007898:0.009291:0.009108:0.006209:0.009039:0.007807:0.005615:0.008834:0.009039:0.006346:0.009291:0.006346:0.006163:0.011413:0.017485:0.010843:0.007807:0.006346:0.009085:0.011596:0.011391:0.006346:0.009106:0.009085:0.011756:0.006346:0.011254:0.009039:0.006346:0.009108:0.010089:0.011160:0.005182:0.010843:0.005273:0.006209:0.009108:0.011391:0.006346:0.005615:0.011756:0.006346:0.011391:0.005615:0.005969:0.005787:0.009039:0.007442:0.009039:0.011391:0.006437:0.006346:0.014723:0.008925:0.009724:0.007670:0.004497:0.006346:0.019083:0.009085:0.005615:0.011870:0.005182:0.009724:0.006346:0.006620:0.011459:0.007442:0.010820:0.011413:0.009927:0.011459:0.006346:0.006551:0.009085:0.007624:0.009656:0.009131:0.006209:0.009108:0.011391:0.004109
treatments that inhibit the growth advantages conferred by driver mutations, killing :@0.117647:0.224167:0.857093:0.224167:0.857093:0.203794:0.117647:0.203794:0.006437:0.007442:0.009291:0.008811:0.006437:0.017485:0.009039:0.011391:0.006437:0.007670:0.007510:0.006620:0.011391:0.008811:0.006437:0.007510:0.005615:0.011870:0.011459:0.005547:0.010820:0.005273:0.006437:0.007510:0.006620:0.011299:0.009039:0.007510:0.009861:0.007442:0.010866:0.014723:0.006617:0.011459:0.007510:0.009291:0.011322:0.009838:0.009085:0.011391:0.006551:0.009199:0.009656:0.009039:0.007670:0.007510:0.008994:0.010843:0.011756:0.006024:0.009039:0.007807:0.007442:0.009108:0.011391:0.007510:0.010843:0.009724:0.007510:0.011391:0.007807:0.005547:0.009633:0.009039:0.007807:0.007510:0.017280:0.011071:0.006551:0.008811:0.006437:0.005547:0.010843:0.011619:0.007670:0.004497:0.007510:0.010706:0.005752:0.005387:0.005250:0.005615:0.011459:0.009861:0.004109
specifically the cancer cells. However, passenger events can also be used as cancer tags :@0.117647:0.244745:0.857116:0.244745:0.857116:0.224373:0.117647:0.224373:0.007510:0.011505:0.009108:0.008994:0.005615:0.005684:0.005615:0.009108:0.009402:0.005387:0.005182:0.009724:0.005615:0.006620:0.011299:0.009039:0.005604:0.009108:0.009085:0.011598:0.008994:0.009039:0.007807:0.005604:0.008994:0.008948:0.005387:0.005250:0.007670:0.004497:0.005604:0.016207:0.010866:0.014518:0.009336:0.009633:0.009039:0.006255:0.004497:0.005615:0.011365:0.009291:0.007533:0.007875:0.009039:0.011459:0.009656:0.009039:0.007807:0.005615:0.009336:0.009633:0.009039:0.011391:0.006437:0.007670:0.005604:0.009108:0.009085:0.011756:0.005615:0.009405:0.005250:0.007875:0.011048:0.005604:0.011254:0.009039:0.005615:0.011413:0.007873:0.009108:0.011391:0.005615:0.009291:0.007670:0.005604:0.009108:0.009085:0.011596:0.008994:0.009039:0.007807:0.005615:0.006551:0.009199:0.009724:0.007670:0.004109
to differentiate tumors from normal cells and measure cancer dynamics. It is therefore :@0.117647:0.265324:0.857098:0.265324:0.857098:0.244951:0.117647:0.244951:0.006209:0.011048:0.005478:0.011391:0.005615:0.005969:0.005787:0.009039:0.007442:0.009039:0.011391:0.006437:0.005798:0.008811:0.006209:0.009039:0.005478:0.006163:0.011413:0.017485:0.010843:0.007624:0.007670:0.005478:0.006412:0.007444:0.010843:0.017645:0.005478:0.011596:0.010843:0.007807:0.017577:0.009405:0.005250:0.005478:0.008994:0.008948:0.005387:0.005250:0.007670:0.005478:0.009085:0.011598:0.011391:0.005478:0.017485:0.009291:0.009291:0.007510:0.011413:0.007442:0.009039:0.005478:0.009108:0.009085:0.011596:0.008994:0.009039:0.007807:0.005478:0.011322:0.009724:0.011687:0.009085:0.017645:0.005545:0.008994:0.007670:0.004497:0.005478:0.006255:0.006437:0.005478:0.005615:0.007670:0.005478:0.006620:0.011299:0.009039:0.007442:0.009039:0.006026:0.010843:0.007442:0.009039:0.004109
possible to turn cancer’s biggest strengths, the acquired mutations and growth advantag-:@0.117647:0.285903:0.852941:0.285903:0.852941:0.265530:0.117647:0.265530:0.011505:0.010957:0.007533:0.007601:0.005547:0.010911:0.005182:0.009039:0.003958:0.006209:0.011048:0.003960:0.006163:0.011413:0.007807:0.011756:0.003958:0.009108:0.009085:0.011596:0.008994:0.009039:0.007076:0.001735:0.007670:0.003960:0.010820:0.005615:0.009975:0.009653:0.009039:0.007512:0.006437:0.003958:0.007510:0.006437:0.007442:0.009039:0.011459:0.009861:0.006620:0.011322:0.007670:0.004497:0.003960:0.006620:0.011299:0.009039:0.003958:0.009291:0.008994:0.010706:0.011413:0.005615:0.007442:0.009108:0.011391:0.003958:0.017280:0.011071:0.006551:0.008811:0.006437:0.005547:0.010843:0.011619:0.007670:0.003960:0.009085:0.011596:0.011391:0.003958:0.009861:0.007442:0.010866:0.014723:0.006620:0.011459:0.003960:0.009291:0.011322:0.009838:0.009085:0.011391:0.006551:0.009199:0.009861:0.007533
es, into its pitfall by leveraging genomic technologies for research and patients’ benefit. :@0.117647:0.306482:0.857027:0.306482:0.857027:0.286109:0.117647:0.286109:0.009039:0.007670:0.004497:0.005364:0.005615:0.011391:0.006209:0.011048:0.005364:0.005273:0.006437:0.007670:0.005364:0.011069:0.005273:0.006437:0.006209:0.009405:0.005387:0.005250:0.005364:0.010843:0.009724:0.005364:0.005182:0.009336:0.009633:0.009039:0.007898:0.009199:0.009861:0.005615:0.011459:0.009861:0.005364:0.009658:0.009039:0.011596:0.010843:0.017645:0.005547:0.008994:0.005364:0.006209:0.009108:0.008763:0.011459:0.011598:0.010934:0.005182:0.011048:0.009861:0.005545:0.009039:0.007670:0.005364:0.006024:0.010845:0.007807:0.005364:0.007442:0.009039:0.007875:0.009291:0.009085:0.007442:0.008765:0.011459:0.005364:0.009085:0.011596:0.011391:0.005364:0.011368:0.008811:0.006437:0.005547:0.009039:0.011391:0.006437:0.006277:0.004291:0.005364:0.011254:0.009039:0.011596:0.009039:0.005684:0.005341:0.006437:0.004497:0.004109
In this final chapter, I summarize several technological contributions presented in the :@0.117647:0.327060:0.857118:0.327060:0.857118:0.306687:0.117647:0.306687:0.006894:0.011756:0.006003:0.006620:0.011459:0.005615:0.007670:0.006003:0.005684:0.005684:0.011690:0.009402:0.005250:0.006003:0.008765:0.011391:0.008811:0.011048:0.006209:0.009039:0.006255:0.004497:0.006003:0.007259:0.006003:0.007510:0.011413:0.017645:0.017577:0.009085:0.007807:0.005615:0.008834:0.009039:0.006003:0.007875:0.009336:0.009633:0.009039:0.007896:0.009405:0.005250:0.006003:0.006209:0.009108:0.008765:0.011459:0.011596:0.010934:0.005182:0.011048:0.009861:0.005547:0.009108:0.009405:0.005250:0.006003:0.008994:0.010843:0.011391:0.006437:0.007807:0.005547:0.010797:0.011071:0.006437:0.005547:0.010843:0.011619:0.007670:0.006003:0.011071:0.007442:0.009039:0.007875:0.009039:0.011391:0.006209:0.009108:0.011391:0.006003:0.005615:0.011756:0.006003:0.006620:0.011299:0.009039:0.004109
previous chapters and discuss their potential and limitations.:@0.117647:0.347639:0.626840:0.347639:0.626840:0.327266:0.117647:0.327266:0.011071:0.007442:0.009336:0.009838:0.005547:0.010820:0.011413:0.007670:0.004109:0.008765:0.011391:0.008811:0.011048:0.006209:0.009039:0.007624:0.007670:0.004109:0.009085:0.011596:0.011391:0.004109:0.011391:0.005615:0.007873:0.009108:0.011413:0.007533:0.007670:0.004109:0.006620:0.011299:0.009039:0.005615:0.007807:0.004109:0.011505:0.010820:0.006209:0.009039:0.011391:0.006437:0.005798:0.009405:0.005250:0.004109:0.009083:0.011598:0.011391:0.004109:0.005250:0.005615:0.017645:0.005271:0.006551:0.008811:0.006437:0.005547:0.010843:0.011619:0.007670:0.004497
Organoids as a tool for ovarian cancer research:@0.117647:0.386855:0.558802:0.386855:0.558802:0.363695:0.117647:0.363695:0.011256:0.011081:0.011056:0.010558:0.011679:0.011256:0.004856:0.011231:0.010409:0.003733:0.010409:0.010409:0.003735:0.010309:0.003984:0.008516:0.011256:0.011256:0.008442:0.003984:0.008840:0.011256:0.011231:0.003984:0.011106:0.009288:0.010558:0.011231:0.004856:0.010558:0.011679:0.003984:0.010905:0.010558:0.011679:0.011007:0.009363:0.011231:0.003984:0.011231:0.009211:0.010409:0.009363:0.010558:0.011081:0.011007:0.011579
Patient-derived cell lines are useful models that are nowadays relatively easy to estab-:@0.117647:0.436421:0.852941:0.436421:0.852941:0.416048:0.117647:0.416048:0.011413:0.008811:0.006437:0.005547:0.009039:0.011391:0.006437:0.007533:0.011322:0.009039:0.007807:0.005547:0.009633:0.009108:0.011391:0.006232:0.008994:0.008948:0.005387:0.005250:0.006232:0.005250:0.005615:0.011596:0.009039:0.007670:0.006232:0.009087:0.007442:0.009039:0.006232:0.011413:0.007875:0.009039:0.006369:0.011550:0.005250:0.006232:0.017488:0.011274:0.011322:0.008948:0.005250:0.007670:0.006232:0.006620:0.011391:0.008811:0.006437:0.006232:0.009085:0.007442:0.009039:0.006232:0.011598:0.010866:0.014723:0.009291:0.011571:0.008925:0.009724:0.007670:0.006232:0.007442:0.008948:0.005433:0.008811:0.006437:0.005547:0.009633:0.008948:0.005182:0.009724:0.006232:0.009291:0.009291:0.007761:0.009724:0.006232:0.006209:0.011048:0.006232:0.009039:0.007510:0.006551:0.009108:0.010929:0.007533
lish, maintain, genetically manipulate and are amenable to large high-throughput drug :@0.117647:0.457000:0.857029:0.457000:0.857029:0.436627:0.117647:0.436627:0.005250:0.005615:0.007556:0.011459:0.004497:0.005250:0.017577:0.009085:0.005615:0.011391:0.006551:0.009085:0.005615:0.011756:0.004497:0.005250:0.009656:0.009039:0.011596:0.009131:0.006437:0.005547:0.009106:0.009405:0.005387:0.005182:0.009724:0.005250:0.017577:0.009085:0.011756:0.005273:0.011048:0.011550:0.005433:0.008811:0.006209:0.009039:0.005250:0.009085:0.011596:0.011391:0.005250:0.009085:0.007442:0.009039:0.005250:0.009085:0.017488:0.009039:0.011687:0.009108:0.010909:0.005184:0.009039:0.005250:0.006209:0.011048:0.005250:0.005433:0.009085:0.007624:0.009656:0.009039:0.005250:0.011459:0.005615:0.009930:0.011459:0.007533:0.006620:0.011459:0.007442:0.010820:0.011413:0.009930:0.011094:0.011048:0.011071:0.006437:0.005250:0.011391:0.007967:0.011413:0.009861:0.004109
screening. However, more complex models represent the complexity and heterogeneity :@0.117647:0.477579:0.857050:0.477579:0.857050:0.457206:0.117647:0.457206:0.007875:0.008994:0.007442:0.009108:0.009039:0.011756:0.005615:0.011459:0.009679:0.004497:0.004794:0.016205:0.010866:0.014518:0.009336:0.009633:0.009039:0.006255:0.004497:0.004794:0.017485:0.010845:0.007442:0.009039:0.004794:0.008994:0.010840:0.017280:0.011162:0.005184:0.009106:0.010089:0.004794:0.017485:0.011276:0.011322:0.008948:0.005250:0.007670:0.004794:0.007442:0.009131:0.011071:0.007442:0.009039:0.007875:0.009039:0.011391:0.006437:0.004794:0.006620:0.011299:0.009039:0.004794:0.008994:0.010843:0.017280:0.011162:0.005182:0.009108:0.010089:0.005273:0.006437:0.009724:0.004794:0.009085:0.011596:0.011391:0.004794:0.011299:0.009131:0.006209:0.009039:0.007442:0.011048:0.009656:0.009039:0.011596:0.009039:0.005273:0.006437:0.009724:0.004109
of tumors better. Patient-derived xenografts are :@0.117647:0.498157:0.517937:0.498157:0.517937:0.477785:0.117647:0.477785:0.010843:0.006209:0.004177:0.006163:0.011413:0.017485:0.010843:0.007624:0.007670:0.004177:0.011254:0.009131:0.006163:0.006209:0.009039:0.006255:0.004497:0.004177:0.011413:0.008811:0.006437:0.005547:0.009039:0.011391:0.006437:0.007533:0.011322:0.009039:0.007807:0.005547:0.009633:0.009108:0.011391:0.004177:0.009884:0.009039:0.011596:0.011048:0.009861:0.007898:0.009085:0.006197:0.006197:0.007670:0.004177:0.009085:0.007442:0.009039:0.004109
in vivo:@0.518025:0.498157:0.572193:0.498157:0.572193:0.477574:0.518025:0.477574:0.005090:0.011299:0.004269:0.009291:0.005159:0.009131:0.009930
 mice models that provide a more :@0.572197:0.498157:0.857030:0.498157:0.857030:0.477785:0.572197:0.477785:0.004177:0.017645:0.005547:0.008994:0.009039:0.004177:0.017485:0.011276:0.011322:0.008948:0.005250:0.007670:0.004177:0.006620:0.011391:0.008811:0.006437:0.004177:0.011071:0.007442:0.010866:0.009838:0.005547:0.011322:0.009039:0.004177:0.009291:0.004177:0.017485:0.010843:0.007442:0.009039:0.004109
realistic tumor environment, therefore increasing the predictive value of drug screens. :@0.117647:0.518736:0.856979:0.518736:0.856979:0.498363:0.117647:0.498363:0.007442:0.009291:0.009405:0.005250:0.005615:0.007510:0.006437:0.005547:0.008994:0.005798:0.006163:0.011413:0.017485:0.010843:0.007807:0.005798:0.009039:0.011368:0.009838:0.005615:0.007442:0.010843:0.011756:0.017485:0.009039:0.011391:0.006437:0.004497:0.005798:0.006617:0.011302:0.009039:0.007442:0.009039:0.006024:0.010845:0.007442:0.009039:0.005798:0.005615:0.011596:0.008994:0.007442:0.009291:0.009291:0.007599:0.005615:0.011459:0.009861:0.005798:0.006620:0.011299:0.009039:0.005798:0.011069:0.007442:0.009108:0.011391:0.005547:0.009108:0.006437:0.005547:0.009633:0.009039:0.005798:0.009838:0.009405:0.004908:0.011345:0.009039:0.005798:0.010843:0.006209:0.005798:0.011391:0.007967:0.011413:0.009861:0.005798:0.007875:0.008994:0.007444:0.009106:0.009039:0.011619:0.007670:0.004497:0.004109
They are however expensive, labor-intense and less suitable for large screening. More-:@0.117647:0.539315:0.852941:0.539315:0.852941:0.518942:0.117647:0.518942:0.011470:0.011311:0.009336:0.009724:0.005866:0.009085:0.007442:0.009039:0.005866:0.011299:0.010866:0.014518:0.009336:0.009633:0.009039:0.007807:0.005866:0.009108:0.010089:0.011505:0.009039:0.011619:0.007601:0.005547:0.009633:0.008743:0.004497:0.005866:0.005433:0.009108:0.011254:0.010843:0.007236:0.007533:0.005615:0.011391:0.006209:0.009039:0.011617:0.007875:0.009039:0.005866:0.009085:0.011598:0.011391:0.005866:0.005182:0.009039:0.007533:0.007670:0.005866:0.007510:0.011413:0.005273:0.006551:0.009108:0.010911:0.005182:0.009039:0.005866:0.006024:0.010845:0.007807:0.005866:0.005433:0.009085:0.007624:0.009656:0.009039:0.005866:0.007875:0.008994:0.007444:0.009106:0.009039:0.011756:0.005615:0.011459:0.009679:0.004497:0.005866:0.018969:0.010845:0.007442:0.009035:0.007533
over, these xenografts might evolve towards a mouse-specific setting that, despite being :@0.117647:0.559894:0.856956:0.559894:0.856956:0.539521:0.117647:0.539521:0.010866:0.009633:0.009039:0.006255:0.004497:0.004839:0.006620:0.011299:0.009039:0.007875:0.009039:0.004839:0.009884:0.009039:0.011596:0.011048:0.009861:0.007898:0.009085:0.006197:0.006197:0.007670:0.004839:0.017645:0.005615:0.009930:0.011094:0.006437:0.004839:0.009336:0.009633:0.010934:0.005182:0.009633:0.009039:0.004839:0.006209:0.010866:0.014723:0.009085:0.007442:0.011391:0.007670:0.004839:0.009291:0.004839:0.017485:0.010820:0.011413:0.007875:0.009039:0.007533:0.007508:0.011505:0.009108:0.008994:0.005615:0.005684:0.005615:0.008994:0.004839:0.007875:0.009128:0.006163:0.006437:0.005615:0.011459:0.009861:0.004839:0.006620:0.011391:0.008811:0.006437:0.004497:0.004839:0.011322:0.009039:0.007510:0.011071:0.005273:0.006209:0.009039:0.004839:0.011254:0.009039:0.005615:0.011459:0.009861:0.004109
in vivo:@0.117647:0.580472:0.172819:0.580472:0.172819:0.559889:0.117647:0.559889:0.005090:0.011299:0.005273:0.009291:0.005159:0.009131:0.009930
 models, deviates from the original tumor’s biology . Patient-derived organoids :@0.172819:0.580472:0.857051:0.580472:0.857051:0.560099:0.172819:0.560099:0.005159:0.017485:0.011276:0.011322:0.008948:0.005250:0.007670:0.004497:0.005159:0.011322:0.009336:0.009838:0.005798:0.008811:0.006209:0.009039:0.007670:0.005159:0.006412:0.007442:0.010843:0.017645:0.005159:0.006620:0.011299:0.009039:0.005159:0.010843:0.007807:0.005615:0.009861:0.005615:0.011687:0.009405:0.005250:0.005159:0.006163:0.011413:0.017485:0.010843:0.007076:0.001735:0.007670:0.005159:0.010820:0.005547:0.010934:0.005182:0.011048:0.010546:0.009724:0.018240:0.004497:0.005159:0.011413:0.008811:0.006437:0.005547:0.009039:0.011391:0.006437:0.007533:0.011322:0.009039:0.007807:0.005547:0.009633:0.009108:0.011391:0.005159:0.010843:0.007624:0.009861:0.009085:0.011596:0.010843:0.005547:0.011391:0.007670:0.004109
115:@0.604969:0.572856:0.623214:0.572856:0.623214:0.560979:0.604969:0.560979:0.006082:0.006082:0.006082
(PDOs) are faithful :@0.117647:0.601051:0.286038:0.601051:0.286038:0.580678:0.117647:0.580678:0.006939:0.011664:0.016504:0.016253:0.007670:0.006939:0.005465:0.009085:0.007442:0.009039:0.005467:0.006209:0.009085:0.005273:0.006620:0.011459:0.006369:0.011550:0.005250:0.004109
in vitro:@0.287395:0.601051:0.346973:0.601051:0.346973:0.580468:0.287395:0.580468:0.005090:0.011299:0.005593:0.009291:0.005205:0.005866:0.007305:0.009930
 representations of the tumor characteristics, such as tumor :@0.346967:0.601051:0.857052:0.601051:0.857052:0.580678:0.346967:0.580678:0.005467:0.007442:0.009131:0.011071:0.007442:0.009039:0.007875:0.009039:0.011391:0.006551:0.008811:0.006437:0.005547:0.010840:0.011621:0.007670:0.005465:0.010843:0.006209:0.005467:0.006620:0.011299:0.009039:0.005467:0.006163:0.011413:0.017485:0.010843:0.007807:0.005467:0.008765:0.011391:0.009085:0.007898:0.009291:0.009108:0.006209:0.009039:0.007807:0.005615:0.007510:0.006437:0.005547:0.008994:0.007670:0.004497:0.005467:0.007510:0.011345:0.008765:0.011459:0.005467:0.009291:0.007670:0.005467:0.006163:0.011413:0.017485:0.010843:0.007807:0.004109
heterogeneity and genomic traits, while allowing for high-throughput drug screening :@0.117647:0.621630:0.857050:0.621630:0.857050:0.601257:0.117647:0.601257:0.011299:0.009131:0.006209:0.009039:0.007442:0.011048:0.009656:0.009039:0.011596:0.009039:0.005273:0.006437:0.009724:0.006574:0.009085:0.011596:0.011391:0.006574:0.009656:0.009039:0.011596:0.010843:0.017645:0.005547:0.008994:0.006574:0.006437:0.007898:0.009085:0.005273:0.006437:0.007670:0.004497:0.006574:0.014792:0.011459:0.005752:0.005182:0.009039:0.006574:0.009405:0.005387:0.005182:0.010866:0.014723:0.005615:0.011459:0.009861:0.006574:0.006026:0.010843:0.007807:0.006574:0.011459:0.005615:0.009927:0.011459:0.007533:0.006620:0.011459:0.007442:0.010820:0.011413:0.009930:0.011094:0.011048:0.011071:0.006437:0.006574:0.011391:0.007967:0.011413:0.009861:0.006574:0.007875:0.008994:0.007442:0.009108:0.009039:0.011756:0.005615:0.011459:0.009861:0.004109
and genetic manipulation. PDOs have the potential to make personalized and targeted :@0.117647:0.642208:0.857032:0.642208:0.857032:0.621835:0.117647:0.621835:0.009085:0.011596:0.011391:0.005159:0.009656:0.009039:0.011596:0.009131:0.006437:0.005547:0.008994:0.005159:0.017577:0.009085:0.011756:0.005273:0.011048:0.011550:0.005433:0.008811:0.006437:0.005547:0.010843:0.011756:0.004497:0.005159:0.011667:0.016501:0.016253:0.007670:0.005159:0.011391:0.008925:0.009633:0.009039:0.005159:0.006620:0.011299:0.009039:0.005159:0.011505:0.010820:0.006209:0.009039:0.011391:0.006437:0.005798:0.009405:0.005250:0.005159:0.006209:0.011048:0.005159:0.017577:0.009405:0.010272:0.009039:0.005159:0.011505:0.009039:0.007624:0.007875:0.010843:0.011687:0.009405:0.005250:0.005615:0.008834:0.009108:0.011391:0.005159:0.009087:0.011596:0.011391:0.005159:0.006551:0.009085:0.007624:0.009656:0.009131:0.006209:0.009108:0.011391:0.004109
treatments for patients with ovarian cancer (OC) a reality and to be important model :@0.117647:0.662787:0.856984:0.662787:0.856984:0.642414:0.117647:0.642414:0.006437:0.007442:0.009291:0.008811:0.006437:0.017485:0.009039:0.011391:0.006437:0.007670:0.005958:0.006026:0.010843:0.007807:0.005958:0.011368:0.008811:0.006437:0.005547:0.009039:0.011391:0.006437:0.007670:0.005958:0.014723:0.005273:0.006620:0.011459:0.005958:0.010866:0.009838:0.009085:0.007807:0.005798:0.009085:0.011756:0.005958:0.009108:0.009085:0.011596:0.008994:0.009039:0.007807:0.005958:0.006939:0.016778:0.014678:0.006939:0.005958:0.009291:0.005958:0.007442:0.009291:0.009405:0.005250:0.005273:0.006437:0.009724:0.005958:0.009087:0.011596:0.011391:0.005958:0.006209:0.011048:0.005958:0.011254:0.009039:0.005958:0.005615:0.017280:0.011502:0.010843:0.007967:0.006551:0.009085:0.011391:0.006437:0.005958:0.017485:0.011276:0.011322:0.008948:0.005250:0.004109
systems to improve our knowledge of cancer biology. :@0.117647:0.683366:0.565757:0.683366:0.565757:0.662993:0.117647:0.662993:0.007761:0.009724:0.007510:0.006209:0.009039:0.017508:0.007670:0.004109:0.006209:0.011048:0.004109:0.005615:0.017280:0.011071:0.007442:0.010866:0.009633:0.009039:0.004109:0.010820:0.011413:0.007807:0.004109:0.010703:0.011598:0.010866:0.014789:0.005182:0.009108:0.011391:0.009656:0.009039:0.004109:0.010843:0.006209:0.004109:0.009108:0.009085:0.011596:0.008994:0.009039:0.007807:0.004109:0.010820:0.005547:0.010934:0.005182:0.011048:0.010546:0.007989:0.004497:0.004109
In :@0.117647:0.724523:0.140405:0.724523:0.140405:0.704150:0.117647:0.704150:0.006894:0.011756:0.004109
chapter 2:@0.141010:0.724523:0.223392:0.724523:0.223392:0.703390:0.141010:0.703390:0.009085:0.011779:0.009542:0.011733:0.006871:0.009268:0.008583:0.004611:0.010911
 we describe a biobank of OC PDOs. This biobank represents multiple dif-:@0.223389:0.724523:0.852941:0.724523:0.852941:0.704150:0.223389:0.704150:0.004714:0.014518:0.009039:0.004714:0.011322:0.009039:0.007875:0.008994:0.007807:0.005547:0.011251:0.009039:0.004714:0.009291:0.004714:0.010820:0.005547:0.010957:0.011117:0.009085:0.011870:0.010523:0.004714:0.010843:0.006209:0.004711:0.016778:0.014678:0.004714:0.011664:0.016504:0.016253:0.007670:0.004497:0.004714:0.011470:0.011470:0.005615:0.007670:0.004711:0.010820:0.005547:0.010957:0.011117:0.009085:0.011870:0.010523:0.004714:0.007442:0.009131:0.011071:0.007442:0.009039:0.007875:0.009039:0.011391:0.006437:0.007670:0.004714:0.017280:0.011550:0.004908:0.006437:0.005273:0.011162:0.005182:0.009039:0.004711:0.011391:0.005615:0.006207:0.007533
ferent OC subtypes and is largely characterized at the histological, genomic, epigenomic :@0.117647:0.745102:0.857121:0.745102:0.857121:0.724729:0.117647:0.724729:0.006026:0.009039:0.007442:0.009039:0.011391:0.006437:0.004132:0.016778:0.014678:0.004132:0.007510:0.011345:0.010797:0.006437:0.009724:0.011505:0.009039:0.007670:0.004132:0.009085:0.011596:0.011391:0.004132:0.005615:0.007670:0.004132:0.005430:0.009087:0.007624:0.009656:0.008948:0.005182:0.009724:0.004132:0.008765:0.011391:0.009085:0.007898:0.009291:0.009108:0.006209:0.009039:0.007807:0.005615:0.008834:0.009108:0.011391:0.004132:0.008811:0.006437:0.004132:0.006620:0.011299:0.009039:0.004132:0.011459:0.005615:0.007510:0.006209:0.010934:0.005182:0.011048:0.009861:0.005547:0.009108:0.009405:0.004976:0.004497:0.004132:0.009656:0.009039:0.011596:0.010843:0.017645:0.005547:0.008994:0.004497:0.004132:0.009131:0.011071:0.005615:0.009656:0.009039:0.011596:0.010843:0.017645:0.005547:0.008994:0.004109
and transcriptomic level, demonstrating the faithfulness to the original tumor material :@0.117647:0.765681:0.857027:0.765681:0.857027:0.745308:0.117647:0.745308:0.009085:0.011596:0.011391:0.005250:0.006437:0.007898:0.009085:0.011619:0.007875:0.008994:0.007807:0.005273:0.011048:0.006209:0.010843:0.017645:0.005547:0.008994:0.005250:0.005182:0.009336:0.009633:0.008948:0.004976:0.004497:0.005250:0.011322:0.009039:0.017485:0.010843:0.011619:0.007510:0.006437:0.007898:0.008811:0.006437:0.005615:0.011459:0.009861:0.005250:0.006620:0.011299:0.009039:0.005250:0.006209:0.009085:0.005273:0.006617:0.011459:0.006369:0.011550:0.005250:0.011596:0.009039:0.007533:0.007670:0.005250:0.006209:0.011048:0.005250:0.006620:0.011299:0.009039:0.005250:0.010843:0.007807:0.005615:0.009861:0.005615:0.011687:0.009405:0.005250:0.005250:0.006163:0.011413:0.017485:0.010843:0.007807:0.005250:0.017577:0.008811:0.006209:0.009039:0.007807:0.005798:0.009405:0.005250:0.004109
and stability over time. Furthermore, creating PDO biobanks of OC and other cancer :@0.117647:0.786259:0.857075:0.786259:0.857075:0.765886:0.117647:0.765886:0.009085:0.011596:0.011391:0.005912:0.007510:0.006551:0.009108:0.010820:0.005752:0.005250:0.005273:0.006437:0.009724:0.005912:0.010866:0.009633:0.009039:0.007807:0.005912:0.006437:0.005615:0.017483:0.008743:0.004497:0.005912:0.010729:0.011413:0.007964:0.006620:0.011302:0.009039:0.007807:0.017483:0.010845:0.007442:0.008743:0.004497:0.005912:0.008994:0.007442:0.009291:0.008811:0.006437:0.005615:0.011459:0.009861:0.005912:0.011664:0.016504:0.016412:0.005912:0.010820:0.005547:0.010957:0.011117:0.009085:0.011870:0.010523:0.007670:0.005912:0.010843:0.006209:0.005912:0.016778:0.014678:0.005912:0.009085:0.011596:0.011391:0.005912:0.010820:0.006620:0.011299:0.009039:0.007807:0.005912:0.009108:0.009087:0.011596:0.008994:0.009039:0.007807:0.004109
types provides platforms for large scale drug screening and genomic and functional :@0.117647:0.806838:0.857002:0.806838:0.857002:0.786465:0.117647:0.786465:0.006437:0.009724:0.011505:0.009039:0.007670:0.007578:0.011071:0.007442:0.010866:0.009838:0.005547:0.011322:0.009039:0.007670:0.007578:0.011162:0.005430:0.008811:0.006437:0.006026:0.010843:0.007807:0.017508:0.007670:0.007578:0.006026:0.010843:0.007807:0.007578:0.005433:0.009085:0.007624:0.009656:0.009039:0.007578:0.007875:0.009108:0.009405:0.005182:0.009039:0.007578:0.011391:0.007964:0.011413:0.009861:0.007578:0.007875:0.008994:0.007442:0.009108:0.009039:0.011756:0.005615:0.011459:0.009861:0.007578:0.009085:0.011596:0.011391:0.007578:0.009656:0.009039:0.011596:0.010843:0.017645:0.005547:0.008994:0.007578:0.009085:0.011596:0.011391:0.007578:0.006369:0.011413:0.011596:0.009108:0.006437:0.005547:0.010843:0.011687:0.009405:0.005250:0.004109
studies, as previously shown for colorectal cancer. The establishment of healthy fallopian :@0.117647:0.827417:0.857004:0.827417:0.857004:0.807044:0.117647:0.807044:0.007510:0.006163:0.011345:0.011391:0.005547:0.009039:0.007670:0.004497:0.003789:0.009291:0.007670:0.003789:0.011071:0.007442:0.009336:0.009838:0.005547:0.010820:0.011413:0.007556:0.005182:0.009724:0.003789:0.007556:0.011299:0.010866:0.014723:0.011756:0.003789:0.006024:0.010845:0.007807:0.003789:0.008994:0.010934:0.005182:0.010845:0.007442:0.009108:0.009106:0.006551:0.009405:0.005250:0.003789:0.009108:0.009085:0.011596:0.008994:0.009039:0.006255:0.004497:0.003789:0.011470:0.011311:0.009039:0.003789:0.009039:0.007510:0.006551:0.009108:0.010911:0.005250:0.005615:0.007556:0.011459:0.017485:0.009039:0.011391:0.006437:0.003789:0.010843:0.006209:0.003789:0.011299:0.009288:0.009405:0.004908:0.006620:0.011071:0.009724:0.003789:0.006209:0.009405:0.005387:0.005182:0.010820:0.011071:0.005798:0.009085:0.011756:0.004109
tube organoids and patient-derived OC organoids has been reported independently by :@0.117647:0.847995:0.857096:0.847995:0.857096:0.827622:0.117647:0.827622:0.006163:0.011345:0.011254:0.009039:0.004794:0.010843:0.007624:0.009861:0.009085:0.011596:0.010843:0.005547:0.011391:0.007670:0.004794:0.009085:0.011596:0.011391:0.004794:0.011368:0.008811:0.006437:0.005547:0.009039:0.011391:0.006437:0.007533:0.011322:0.009039:0.007807:0.005547:0.009633:0.009108:0.011391:0.004794:0.016778:0.014678:0.004794:0.010843:0.007624:0.009861:0.009085:0.011596:0.010843:0.005547:0.011391:0.007670:0.004794:0.011391:0.009291:0.007670:0.004794:0.011254:0.009108:0.009039:0.011756:0.004794:0.007442:0.009131:0.011502:0.010845:0.007964:0.006209:0.009108:0.011391:0.004794:0.005615:0.011596:0.011322:0.009131:0.011505:0.009039:0.011596:0.011322:0.009039:0.011391:0.006620:0.005182:0.009724:0.004794:0.010843:0.009724:0.004109
other groups:@0.117647:0.868574:0.224864:0.868574:0.224864:0.848201:0.117647:0.848201:0.010820:0.006620:0.011299:0.009039:0.007807:0.003584:0.009861:0.007442:0.010820:0.011071:0.011185:0.007670
279,309,310,420:@0.224869:0.860958:0.305715:0.860958:0.305715:0.849081:0.224869:0.849081:0.006082:0.006082:0.006082:0.002622:0.006082:0.006082:0.006082:0.002622:0.006082:0.006082:0.006082:0.002622:0.006082:0.006082:0.006082
. All these studies show similar culture success rates to ours, which :@0.305712:0.868574:0.857004:0.868574:0.857004:0.848201:0.305712:0.848201:0.004497:0.003584:0.015066:0.005387:0.005250:0.003584:0.006620:0.011299:0.009039:0.007875:0.009039:0.003584:0.007510:0.006166:0.011345:0.011391:0.005547:0.009039:0.007670:0.003584:0.007558:0.011299:0.010866:0.014723:0.003584:0.007601:0.005615:0.017645:0.005750:0.005433:0.009085:0.007807:0.003584:0.009108:0.011550:0.004908:0.006163:0.011413:0.007442:0.009039:0.003584:0.007510:0.011345:0.008994:0.008994:0.009039:0.007533:0.007670:0.003584:0.007898:0.008811:0.006209:0.009039:0.007670:0.003584:0.006209:0.011048:0.003584:0.010820:0.011413:0.007624:0.007670:0.004497:0.003584:0.014792:0.011459:0.005545:0.008768:0.011459:0.004109
are lower when the obtained resected tumor material has been previously exposed to :@0.117647:0.889153:0.857162:0.889153:0.857162:0.868780:0.117647:0.868780:0.009085:0.007442:0.009039:0.006323:0.005182:0.010866:0.014518:0.009039:0.007807:0.006323:0.014792:0.011299:0.009039:0.011756:0.006323:0.006620:0.011299:0.009039:0.006323:0.010957:0.010797:0.006549:0.009087:0.005615:0.011596:0.009106:0.011391:0.006323:0.007442:0.009039:0.007875:0.009108:0.009108:0.006209:0.009108:0.011391:0.006323:0.006163:0.011413:0.017485:0.010843:0.007807:0.006323:0.017577:0.008811:0.006209:0.009039:0.007807:0.005798:0.009402:0.005250:0.006323:0.011391:0.009291:0.007670:0.006323:0.011254:0.009108:0.009039:0.011756:0.006323:0.011071:0.007442:0.009336:0.009838:0.005547:0.010820:0.011413:0.007556:0.005182:0.009724:0.006323:0.009108:0.010089:0.011505:0.010957:0.007875:0.009108:0.011391:0.006323:0.006209:0.011048:0.004109
treatment, as is the case for most of our PDO lines. These independent studies also show :@0.117647:0.909732:0.856938:0.909732:0.856938:0.889359:0.117647:0.889359:0.006437:0.007442:0.009291:0.008811:0.006437:0.017485:0.009039:0.011391:0.006437:0.004497:0.003972:0.009291:0.007670:0.003972:0.005615:0.007670:0.003972:0.006620:0.011299:0.009039:0.003972:0.009108:0.009291:0.007875:0.009039:0.003972:0.006026:0.010843:0.007807:0.003972:0.017485:0.010957:0.007510:0.006437:0.003972:0.010843:0.006209:0.003972:0.010820:0.011413:0.007807:0.003972:0.011664:0.016504:0.016412:0.003972:0.005250:0.005615:0.011596:0.009039:0.007670:0.004497:0.003972:0.011470:0.011313:0.009039:0.007873:0.009039:0.003972:0.005615:0.011596:0.011322:0.009131:0.011502:0.009039:0.011598:0.011322:0.009039:0.011391:0.006437:0.003972:0.007510:0.006163:0.011345:0.011391:0.005547:0.009039:0.007670:0.003972:0.009405:0.005250:0.007875:0.011048:0.003972:0.007556:0.011302:0.010863:0.014723:0.004109